Travere Therapeutics, Inc.

NasdaqGM:TVTX Lagerbericht

Marktkapitalisierung: US$1.4b

Travere Therapeutics Management

Management Kriterienprüfungen 2/4

Travere Therapeutics' CEO is Eric Dube, appointed in Jan 2019, has a tenure of 5.83 years. total yearly compensation is $7.57M, comprised of 10.5% salary and 89.5% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $2.16M. The average tenure of the management team and the board of directors is 4.1 years and 7.6 years respectively.

Wichtige Informationen

Eric Dube

Geschäftsführender

US$7.6m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts10.5%
Amtszeit als Geschäftsführer5.8yrs
Eigentum des Geschäftsführers0.2%
Durchschnittliche Amtszeit des Managements4.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder7.6yrs

Jüngste Management Updates

Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

May 02
Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

Recent updates

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry

Oct 31
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Oct 07
Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN

Sep 30

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Sep 10
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Travere Therapeutics: Judgement Day Is Nigh For Sparsentan

Aug 30

Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

May 02
Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop

Apr 20
Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop

Travere Therapeutics: Restructuring Away From Disaster

Jan 30

Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jan 22
Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too

Dec 18
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too

New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)

Aug 08
New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Jun 09
Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks

May 05
It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Feb 16
Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Travere Therapeutics' FDA target action date for nephropathy treatment extended

Oct 13

Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?

Oct 06
Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?

Travere Therapeutics: Changes In The Risk-Reward Assessment

Sep 29

Travere, CSL kidney disease drug sparsentan gets review in EU

Aug 22

Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M

Aug 04

Travere Theraspeutics a new buy at Canaccord as a 'rare disease powerhouse'

Jul 14

Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?

Jun 19
Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?

Travere Therapeutics: Strong Sell, Ticking Time Bomb, We Are Passing

Apr 11

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Feb 07
Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Travere Therapeutics: Tarpeyo's Approval Is Good News

Jan 31

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Eric Dube im Vergleich zu den Einnahmen von Travere Therapeutics verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

-US$349m

Jun 30 2024n/an/a

-US$383m

Mar 31 2024n/an/a

-US$416m

Dec 31 2023US$8mUS$796k

-US$376m

Sep 30 2023n/an/a

-US$373m

Jun 30 2023n/an/a

-US$368m

Mar 31 2023n/an/a

-US$352m

Dec 31 2022US$6mUS$747k

-US$331m

Sep 30 2022n/an/a

-US$297m

Jun 30 2022n/an/a

-US$249m

Mar 31 2022n/an/a

-US$202m

Dec 31 2021US$6mUS$708k

-US$217m

Sep 30 2021n/an/a

-US$250m

Jun 30 2021n/an/a

-US$237m

Mar 31 2021n/an/a

-US$224m

Dec 31 2020US$5mUS$661k

-US$169m

Sep 30 2020n/an/a

-US$78m

Jun 30 2020n/an/a

-US$92m

Mar 31 2020n/an/a

-US$105m

Dec 31 2019US$10mUS$618k

-US$146m

Vergütung im Vergleich zum Markt: Eric's total compensation ($USD7.57M) is above average for companies of similar size in the US market ($USD5.64M).

Entschädigung vs. Einkommen: Eric's compensation has increased whilst the company is unprofitable.

Geschäftsführer

Eric Dube (51 yo)

5.8yrs

Amtszeit

US$7,574,959

Vergütung

Dr. Eric M. Dube, Ph D., serves as an Independent Director at Reneo Pharmaceuticals, Inc. since March 2021. Dr. Dube serves as President and Chief Executive Officer at Travere Therapeutics, Inc. (formerly...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Eric Dube
President5.8yrsUS$7.57m0.16%
$ 2.2m
Christopher Cline
Chief Financial Officer2.3yrsUS$1.97m0.098%
$ 1.3m
Elizabeth Reed
Senior VP7.8yrsUS$2.02m0.10%
$ 1.4m
William Rote
Senior VP and Head of Research & Development7.8yrsUS$2.05m0.047%
$ 638.2k
Peter Heerma
Chief Commercial Officer5.1yrsUS$2.00m0.077%
$ 1.1m
Sandra Calvin
SVP, Corporate Controller & Chief Accounting Officer3.2yrskeine Daten0.068%
$ 932.5k
Nivi Nehra
Vice President of Corporate Communications & Investor Relationsno datakeine Datenkeine Daten
Angela Giannantonio
Senior Vice President of Human Resourcesno datakeine Datenkeine Daten
Casey Logan
Chief Business Officerless than a yearkeine Datenkeine Daten
Jula Inrig
Chief Medical Officer2.8yrsUS$2.87m0.081%
$ 1.1m
Charlotte Smith
Senior Vice President of Public Affairsno datakeine Datenkeine Daten

4.1yrs

Durchschnittliche Betriebszugehörigkeit

52yo

Durchschnittliches Alter

Erfahrenes Management: TVTX's management team is considered experienced (4.1 years average tenure).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Eric Dube
President5.8yrsUS$7.57m0.16%
$ 2.2m
John Orwin
Independent Director7.7yrsUS$372.98k0.038%
$ 517.7k
Gary Lyons
Independent Chairman of the Board10.1yrsUS$392.98k0.067%
$ 914.3k
Stuart J. Swiedler
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Suzanne Bruhn
Independent Director4.6yrsUS$372.36k0.029%
$ 398.9k
Roy Baynes
Independent Director8.4yrsUS$376.73k0.041%
$ 555.8k
Ruth Williams-Brinkley
Independent Director3.2yrsUS$365.48k0.025%
$ 345.2k
Timothy Coughlin
Independent Director9.7yrsUS$385.48k0.064%
$ 878.5k
Ron Squarer
Independent Director7.6yrsUS$367.98k0.038%
$ 517.7k
Jeffrey Meckler
Independent Director10.1yrsUS$379.98k0.11%
$ 1.5m
Alan Beggs
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Sandra Poole
Independent Director5.5yrsUS$369.86k0.031%
$ 421.3k

7.6yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrener Vorstand: TVTX's board of directors are considered experienced (7.6 years average tenure).